This study examines how well a medicine called galcanezumab works to prevent migraines in kids and teens aged 6 to 17. A migraine is a strong headache that can make you feel sick and sensitive to light or noise. The study has two parts: the main study and a study addendum. In the main study, participants will be given either galcanezumab or a placebo (a dummy medicine) for 3 months without knowing which one they got. After this, everyone will get galcanezumab for 9 more months. The study addendum involves a different group of participants who will receive a single dose of galcanezumab and be observed for 5 months, followed by 9 months of treatment with galcanezumab.
- This study lasts up to 12 months for the main study and 14 months for the addendum.
- Participants will have several visits to the study site for check-ups and monitoring.
- Risks include possible allergic reactions to the medicine; discuss with your doctor.
To qualify, you must have had migraines for at least 6 months. You cannot participate if you are using certain other medicines or have a history of specific headaches or serious head injuries.